Bionor’s strategy is to develop the combination of its two proprietary therapeutic HIV vaccines Vacc-4x and Vacc-C5 and seek advice on and adapt its regulatory path so that a marketing approval for a functional cure for HIV can be achieved.
As part of this strategy, Bionor will extend and complete the Vacc-C5 dose escalation studies and further advancement of its clinical program for the combination of Vacc-4x and Vacc-C5 used in combination with other adjuvants/medicines.
As part of this development process, Bionor will seek advice from FDA / EMA for the regulatory path and adapt it, so that its clinical development program is well defined and can lead to a marketing approval for the HIV vaccines and a functional cure for HIV.
Bionor will in parallel with these clinical and regulatory developments, seek to form a strategic partnership for its HIV products and pipeline.